| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Chengdu Kanghua Biological Products Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥51.78 |
| 52 Week High | CN¥84.05 |
| 52 Week Low | CN¥44.78 |
| Beta | 2.42 |
| 11 Month Change | -8.81% |
| 3 Month Change | -12.73% |
| 1 Year Change | -15.10% |
| 33 Year Change | -67.09% |
| 5 Year Change | n/a |
| Change since IPO | 14.98% |
Recent News & Updates
Shareholder Returns
| 300841 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 2.3% | -4.1% | -1.4% |
| 1Y | -15.1% | -25.0% | -19.1% |
Return vs Industry: 300841 exceeded the CN Biotechs industry which returned -25% over the past year.
Return vs Market: 300841 exceeded the CN Market which returned -19.1% over the past year.
Price Volatility
| 300841 volatility | |
|---|---|
| 300841 Average Weekly Movement | 4.9% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in CN Market | 10.0% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 300841's share price has been volatile over the past 3 months.
Volatility Over Time: 300841's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 672 | n/a | www.kangh.com |
Chengdu Kanghua Biological Products Co., Ltd. engages in the research, development, production, sale, and technical service of biological products in China. It offers group ACYW135 meningococcal polysaccharide vaccines; and freeze-dried human diploid cell rabies vaccines.
Chengdu Kanghua Biological Products Co., Ltd. Fundamentals Summary
| 300841 fundamental statistics | |
|---|---|
| Market cap | CN¥6.66b |
| Earnings (TTM) | CN¥553.49m |
| Revenue (TTM) | CN¥1.61b |
12.4x
P/E Ratio4.3x
P/S RatioIs 300841 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300841 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.61b |
| Cost of Revenue | CN¥98.75m |
| Gross Profit | CN¥1.51b |
| Other Expenses | CN¥958.40m |
| Earnings | CN¥553.49m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 17, 2024
| Earnings per share (EPS) | 4.17 |
| Gross Margin | 93.87% |
| Net Profit Margin | 34.36% |
| Debt/Equity Ratio | 5.8% |
How did 300841 perform over the long term?
See historical performance and comparison